PeerCurrent.com|Stay current with the people and research shaping what comes next.

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Clinical trial

NCT07717411

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials1 Reviews Guidelines

Latest

Everything in the corpus, newest first.

SEP 10, 2026 · PHASE 3 TRIAL

A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease

ClinicalTrials.gov

This is a clinical trial registry record with no reported results; the study is actively recruiting and designed to evaluate trontinemab in preclinical Alzheimer's disease, but outcome data are not yet available.

PreliminaryNCT07717411 Alzheimer's Disease Trontinemab

Reported

Planned sample size1600

Primary outcome measureTime to Progression, defined as confirmed C…

Planned follow-up durationBaseline up to approximately 6 years

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support